首页> 外文期刊>Journal of the American Society of Hypertension : >Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis
【24h】

Regional and physician specialty-associated variations in the medical management of atherosclerotic renal-artery stenosis

机译:动脉粥样硬化性肾动脉狭窄的医疗管理中与地区和医师专业相关的变化

获取原文
获取原文并翻译 | 示例
           

摘要

For people enrolled in Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), we sought to examine whether variation exists in the baseline medical therapy of different geographic regions and if any variations in prescribing patterns were associated with physician specialty. Patients were grouped by location within the United States (US) and outside the US (OUS), which includes Canada, South America, Europe, South Africa, New Zealand, and Australia. When comparing US to OUS, participants in the US took fewer anti hypertensive medications (1.9 +/- 1.5 vs. 2.4 +/- 1.4; P < .001) and were less likely to be treated with an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker (46% vs. 62%; P < .001), calcium channel antagonist (37% vs. 58%; P < .001), and statin (64% vs. 75%; P < .05). In CORAL, the identification of variations in baseline medical therapy suggests that substantial opportunities exist to improve the medical management of patients with atherosclerotic renal artery stenosis. (C) 2015 American Society of Hypertension. All rights reserved.
机译:对于参加肾动脉粥样硬化病变(CORAL)心血管预后的人群,我们试图检查在不同地理区域的基线药物治疗中是否存在差异,以及处方模式是否与医师专业相关。患者在美国(美国)内和美国以外(OUS)外(包括加拿大,南美,欧洲,南非,新西兰和澳大利亚)进行分组。在将US与OUS进行比较时,美国的参与者服用了较少的抗高血压药物(1.9 +/- 1.5与2.4 +/- 1.4; P <.001),并且接受血管紧张素转换酶抑制剂或血管紧张素II治疗的可能性较小受体阻滞剂(46%vs. 62%; P <.001),钙通道拮抗剂(37%vs. 58%; P <.001)和他汀类药物(64%vs. 75%; P <.05)。在CORAL中,对基线药物治疗变异的鉴定表明存在大量改善动脉粥样硬化性肾动脉狭窄患者的医疗管理的机会。 (C)2015年美国高血压学会。版权所有。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号